887147-20-8

Usage

Uses

Used in Pharmaceutical Industry:
2,6-dichloro-N-Methyl-3-nitropyridin-4-aMine is used as a chemical intermediate for the synthesis of various drugs. Its unique structure and properties make it a valuable component in the development of pharmaceuticals, contributing to the creation of new and effective medications.
Used in Laboratory Research:
In the field of genetic research, 2,6-dichloro-N-Methyl-3-nitropyridin-4-aMine is employed as a mutagen to induce mutations in bacterial DNA. This application is crucial for studying the effects of genetic modifications and understanding the mechanisms of mutation induction, which can further the development of genetic therapies and understanding of genetic diseases.

Upstream product

• 2897-43-0 2,6-dichloro-3-nitropyridin-4-amine 
• 74-88-4 methyl iodide 
• 2587-00-0 2,6-dichloropyridine N-oxide 
• 2402-78-0 2,6-dichloropyridine 
• 1569084-56-5 tert-butyl 2,6-dichloropyridin-4-yl(methyl)carbamate 
• 501907-61-5 tert-butyl (2,6-dichloropyridin-4-yl)carbamate 
• 2587-02-2 2,6-dichloro-[4]pyridylamine 
• 16063-69-7 2,4,6-trichloropyridine 
• 914942-85-1 2,6-dichloro-N-methyl-N-nitro pyridine-4-amine 
• 175461-33-3 2,6-dichloro-N-methylpyridine-4-amine 

Downstream Products

• 914942-86-2 2,6-dichloro-4-N-methylpyridine-3,4-diamine 
• 1043893-80-6 6-chloro-2-(4-chlorophenylamino)-4-methylamino-3-nitropyridine 
• 914944-26-6 3-((4-tert-butyloxycarbonyl(methyl)amino)-1-methyl-6-(2,2,2-trifluoroacetamido)-1H-imidazo[4,5-c]pyridin-7-yl)ethynyl-5-fluorobenzoic acid methyl ester 
• 914943-46-7 N-[[3-[1,5-dihydro-1-methyl-4-(methyl-t-butyloxycarbonylamino)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]phenyl]methyl]trimethylacetamide 
• 914943-90-1 3-[6-amino-4-(tert-butoxycarbonyl-methyl-amino)-1-methyl-1H-imidazo[4,5-d]pyridin-7-ylethynyl]-benzoic acid tert-butyl ester 
• 914944-25-5 3-((6-amino-4-(tert-butyloxycarbonyl(methyl)amino)-1-methyl-1H-imidazo[4,5-c]pyridine-7-yl)ethynyl)-5-fluorobenzoic acid methyl ester 
• 914944-30-2 3-[1,6-dihydro-1-methyl-4-((methyl)tert-butoxycarbonylamino)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]-5-fluoro-benzoic acid 
• 914942-98-6 N-[[3-[1,6-dihydro-1-methyl-4-(methyl-t-butyloxycarbonylamino)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]phenyl]methyl]acetamide 
• 914944-27-7 3-[1,6-dihydro-1-methyl-4-((methyl)tert-butoxycarbonylamino)imidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl]-5-fluoro-benzoic acid methyl ester 
• 914944-37-9 tert-butyl 6-amino-7-(2-(4-cyanophenyl)ethynyl)-1-methyl-1H-imidazo[4,5-c]pyridin-4-yl(methyl)carbamate 
• 914942-92-0 tert-butyl 6-amino-7-(2-(3-cyanophenyl)ethynyl)-1-methyl-1H-imidazo[4,5-c]pyridin-4-yl(methyl)carbamate 
• 914943-95-6 tert-butyl 6-amino-1-methyl-7-(2-(3-bromophenyl)ethynyl)-1H-imidazo[4,5-d]pyridin-4-yl(methyl)carbamate 
• 914944-36-8 7-[4-(aminomethyl)phenyl]-1,5-dihydro-N,1-dimethyl-imidazo[4,5-c]pyrrolo[2,3-b]pyridin-4-(t-butyloxycarbonylamine) 
• 914942-96-4 7-[3-(aminomethyl)phenyl]-1,6-dihydro-N,1-dimethyl-imidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-(t-butyloxycarbonylamine) 

Relevant academic research and scientific papers

Bicyclic compound, preparation method and application thereof

The invention belongs to the field of medicines, and particularly relates to a compound represented by a formula I, a stereoisomer, a tautomer or a mixture of the stereoisomer and the tautomer of thecompound, a pharmaceutically acceptable salt, eutectic, polymorph or solvate of the compound, or a stable isotope derivative, metabolite or prodrug of the compound.

NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS

The present invention discloses compounds according to Formula (I), wherein R1, R3, R4, R5, L1, and Cy are as defined herein. The present invention also provides compounds, methods for the production of said compounds of the invention, pharmaceutical compositions comprising the same and their use in allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 and/or interferons. The present invention also methods for the prevention and/or treatment of the aforementioned diseases by administering a compound of the invention.

Synthesis and evaluation of novel imidazo[4,5-: C] pyridine derivatives as antimycobacterial agents against Mycobacterium tuberculosis

The current study involves the synthesis of novel imidazo[4,5-c]pyridine derivatives (IPD) containing amide/urea/sulfonamide. The synthesized compounds were evaluated for in vitro and in vivo antimycobacterial activities against Mycobacterium tuberculosis. The pharmacological activities were determined by the objective to better understand their structure-activity relationship (SAR) for their in vitro antimycobacterial activity against M. tuberculosis. Some synthesized compounds showed significant activity against M. tuberculosis based on the agar dilution method. Among the forty-one compounds screened, compounds 21, 22 and 23 were found to be the most active compounds against M. tuberculosis. In the in vivo animal model, 21, 22 and 23 decreased the bacterial load in lung and spleen tissues at the dose of 50 mg kg-1 body weight.

NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF

The present invention relates to a novel triazolopyrimidinone or triazolopyridinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.

ALKYNYL ALCOHOLS AND METHODS OF USE

The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

ALKYNYL ALCOHOLS AND METHODS OF USE

The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

PYRIDINYL-PYRAZOLE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS

This invention relates to novel pyridinyl-pyrazole derivatives and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associa

8H-IMIDAZO[4,5-D]THIAZOLO[4,5-B]PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME

The present invention provides for thiazolopyridine-based tricyclic compounds having the formula (I) wherein R1, R2, R5 and R6 are as described herein. The present invention further provides pharmaceutical compo

1, 6 -DIHYDRO- 1,3, 5, 6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS INHIBITORS OF IKK ENZYME ACTIVITY

The present invention provides for tricyclic compounds having the formula (I) wherein R1, R2, R5, R6, R7, and R8 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.